Thursday, January 18, 2018 12:39:59 PM
While this article is somewhat old (2012), given the apparent lack of progress in treating CLI I would expect much of these statistics to remain the same.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440268/
We can see from the clinicaltrials.gov website (https://clinicaltrials.gov/ct2/show/NCT03006770?term=pluristem&rank=1) that the Timeframe for observing the patients is a follow up of 12 to 36 months (and seen from their latest presentation slide 17, and from website too). Thus this should provide ample time to show a clear difference in performance of the placebo vs treatment group.
Also this is why the trial can get preliminary approval early in Europe with the Adaptive Pathways pilot project granted for the CLI Phase III with results from 50% of the randomised sample. Is that once having half the sample we will also be somewhere around 1 year of treatment. Thus the interim data can be compared with such historical data as above, and an analysis of statistical difference can be performed.
They can start with the interim analysis that hopefully will show at worst a trend, or at best already statistically significant benefits.
It is also pertinent to note that in the presentation slide 18, it is stated that for the interim analysis they will also be generating that primary goal on the composite end-point which may facilitate early approval.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM